Immunome Inc

Insider buying at Immunome Inc. signals confidence amid market volatility: 5,000 shares purchased at $20.70, suggesting undervalued biotech potential and a possible rebound.

Immunome Inc’s April 2 insider trades show disciplined, plan‑based selling by senior execs, indicating confidence while the company pushes a CRISPR‑based immunotherapy toward FDA approval and possible partnership.

Immunome insider sales reveal routine liquidity moves, not a red flag, while CEO buying and strong antibody pipeline signal confidence in upcoming FDA milestones and growth potential.